New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up

Breast Cancer Research and Treatment
K C JensenR B West

Abstract

HER2 gene amplification and/or protein overexpression in breast cancer is associated with a poor prognosis and predicts response to anti-HER2 therapy. We examine the natural history of breast cancers in relationship to increased HER2 copy numbers in a large population-based study. HER2 status was measured by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in approximately 1,400 breast cancer cases with greater than 15 years of follow-up. Protein expression was evaluated with two different commercially-available antibodies. We looked for subgroups of breast cancer with different clinical outcomes, based on HER2 FISH amplification ratio. The current HER2 ratio cut point for classifying HER2 positive and negative cases is 2.2. However, we found an increased risk of disease-specific death associated with FISH ratios of >1.5. An 'intermediate' group of cases with HER2 ratios between 1.5 and 2.2 was found to have a significantly better outcome than the conventional 'amplified' group (HER2 ratio >2.2) but a significantly worse outcome than groups with FISH ratios less than 1.5. Breast cancers with increased HER2 copy numbers (low level HER2 amplification), below the currently accepted positive threshold ratio ...Continue Reading

References

Feb 1, 1989·European Journal of Cancer & Clinical Oncology·L L Shek, W Godolphin
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A OlivottoC Sawka
Jul 14, 1998·Nature Medicine·J KononenO P Kallioniemi
Sep 2, 1999·Nature Genetics·J R PollackP O Brown
Feb 5, 2000·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·R E JimenezD W Visscher
Aug 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LohrischI A Olivotto
Aug 30, 2000·Nature·C M PerouD Botstein
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G PaulettiD J Slamon
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Charles L VogelMichael Press
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen K ChiaIvo A Olivotto
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenCharles M Perou
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ivo A OlivottoKaren A Gelmon
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Nov 23, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maggie C U CheangAllen M Gown
Dec 13, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Jan 12, 2007·Journal of Molecular Histology·Lindsay A Brown, David Huntsman
Jan 1, 2007·Archives of Pathology & Laboratory Medicine·Antonio C WolffUNKNOWN American Society of Clinical Oncology/College of American Pathologists
Jul 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
Nov 23, 2013·Journal of the National Cancer Institute·Katherine L Pogue-GeileSoonmyung Paik

❮ Previous
Next ❯

Citations

Sep 21, 2010·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Gulisa TurashviliSamuel A J R Aparicio
Sep 12, 2009·The American Journal of Surgical Pathology·Kristin C JensenRobert B West
Sep 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenMatthew J Ellis
Apr 28, 2009·BMC Medical Genomics·Hideaki MizunoAkinori Sarai
Dec 29, 2010·Pathology Research International·Sejal Shah, Beiyun Chen
Dec 17, 2011·Scandinavian Journal of Gastroenterology·Maria Unni RømerNils Brünner
Oct 2, 2013·Cancer Treatment Reviews·Edith A PerezJohn M S Bartlett
Sep 14, 2016·Journal of Neuro-oncology·Charlotte Aaberg-JessenBjarne W Kristensen
Nov 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wedad M HannaSharon Nofech-Mozes
Oct 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert L CampDavid L Rimm
Apr 16, 2016·World Journal of Clinical Oncology·Frederik Holst
Sep 16, 2008·Nutrition and Cancer·Walter Willett
Jul 21, 2020·Breast Cancer Research and Treatment·Svetlana BortnikSharon M Gorski
Oct 31, 2012·The American Journal of Surgical Pathology·Michael R ClayKristin C Jensen
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carol BeadlingChristopher L Corless
Jun 12, 2021·Frontiers in Oncology·Yue QiQiuyan Guo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.